These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 12324987

  • 1. An overview of insulin glargine.
    Home PD, Ashwell SG.
    Diabetes Metab Res Rev; 2002; 18 Suppl 3():S57-63. PubMed ID: 12324987
    [Abstract] [Full Text] [Related]

  • 2. Innovative insulins--where do analogues fit?
    Phillips LK, Phillips PJ.
    Aust Fam Physician; 2006 Dec; 35(12):969-73. PubMed ID: 17149471
    [Abstract] [Full Text] [Related]

  • 3. Insulin therapy in type 2 diabetes: role of the long-acting insulin glargine analogue.
    Yki-Järvinen H.
    Eur J Clin Invest; 2004 Jun; 34(6):410-6. PubMed ID: 15200492
    [Abstract] [Full Text] [Related]

  • 4. Insulin glargine: long-acting basal insulin analog for improved metabolic control.
    Gerich JE.
    Curr Med Res Opin; 2004 Jan; 20(1):31-7. PubMed ID: 14741069
    [Abstract] [Full Text] [Related]

  • 5. Insulin glargine: a new once-daily basal insulin for the management of type 1 and type 2 diabetes mellitus.
    Lam S.
    Heart Dis; 2003 Jan; 5(3):231-40. PubMed ID: 12783637
    [Abstract] [Full Text] [Related]

  • 6. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir.
    Peterson GE.
    Curr Med Res Opin; 2006 Dec; 22(12):2613-9. PubMed ID: 17166343
    [Abstract] [Full Text] [Related]

  • 7. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H, Kohlmann T, Landgraf W, Holle R, Pirk O, Scholten T.
    Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
    [Abstract] [Full Text] [Related]

  • 8. An update on the long-acting insulin analogue glargine.
    Thisted H, Johnsen SP, Rungby J.
    Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):1-11. PubMed ID: 16867163
    [Abstract] [Full Text] [Related]

  • 9. The role of new basal insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetes.
    Baxter MA.
    Acta Diabetol; 2008 Dec; 45(4):253-68. PubMed ID: 18766296
    [Abstract] [Full Text] [Related]

  • 10. Rational use of insulin analogues in the treatment of type 1 diabetes mellitus.
    Bolli GB.
    Pediatr Endocrinol Rev; 2003 Sep; 1(1):9-21. PubMed ID: 16437009
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis.
    Monami M, Marchionni N, Mannucci E.
    Diabetes Res Clin Pract; 2008 Aug; 81(2):184-9. PubMed ID: 18495286
    [Abstract] [Full Text] [Related]

  • 13. Treatment with insulin glargine does not suppress serum IGF-1.
    Slawik M, Schories M, Busse Grawitz A, Reincke M, Petersen KG.
    Diabet Med; 2006 Jul; 23(7):814-7. PubMed ID: 16842489
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Insulin analogues: place of detemir (Levemir)].
    Dorchy H, Sternon J.
    J Pharm Belg; 2006 Jul; 61(2):58-62. PubMed ID: 16866083
    [Abstract] [Full Text] [Related]

  • 16. Insulin glargine maintains equivalent glycemic control and better lipometabolic control than NPH insulin in type 1 diabetes patients who missed a meal.
    Rosak C, Jung R, Hofmann U.
    Horm Metab Res; 2008 Aug; 40(8):544-8. PubMed ID: 18493882
    [Abstract] [Full Text] [Related]

  • 17. Insulin glargine and receptor-mediated signalling: clinical implications in treating type 2 diabetes.
    Le Roith D.
    Diabetes Metab Res Rev; 2007 Nov; 23(8):593-9. PubMed ID: 17922476
    [Abstract] [Full Text] [Related]

  • 18. Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study.
    Hermansen K, Dornhorst A, Sreenan S.
    Curr Med Res Opin; 2009 Nov; 25(11):2601-8. PubMed ID: 19739940
    [Abstract] [Full Text] [Related]

  • 19. Comparison of the subcutaneous absorption of insulin glargine (Lantus) and NPH insulin in patients with Type 2 diabetes.
    Luzio SD, Beck P, Owens DR.
    Horm Metab Res; 2003 Jul; 35(7):434-8. PubMed ID: 12931275
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.